Adhera Therapeutics Inc (ATRX)

[Jose Chavez]

$ATRX By 2050, the prevalence is expected to rise to 5 million people in the U.S., including nearly 600,000 youth. There are $16 billion in Type 1 diabetes-associated healthcare expenditures and lost income annually in the U.S. Less than one-third of people with Type 1 diabetes in the U.S. are consistently achieving target blood-glucose control levels.